» Articles » PMID: 31193808

To Reveal Pharmacological Targets and Molecular Mechanisms of Curcumol Against Interstitial Cystitis

Overview
Journal J Adv Res
Date 2019 Jun 14
PMID 31193808
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

This study was designed to reveal the predictive targets and biological mechanisms of curcumol against interstitial cystitis (IC). By use of available databases and bioinformatic assays, pathogenetic targets of IC and functional targets of curcumol were identified respectively. A network of functional protein-protein interaction (PPI) was produced before screening the main predictive targets, biological processes and signaling pathways of curcumol against IC. In bioinformatic findings, the data of ingenuity pathway analysis (IPA) delineated that curcumol exerted anti-IC benefits through regulating multipronged signaling pathways, including tyrosine protein kinase-2 (PTK2) pathway. Further, optimal 18 biotargets of curcumol against IC were harvested through differential expression analysis. And the predictive targets of receptor tyrosine-protein kinase erbB-2 (ERBB2), epidermal growth factor receptor (EGFR) and PTK2 were the most important molecules. In further validated experiments, PTK2 and phosphorylation PTK2 (p-PTK2) were representatively selected for testing by human and animal IC samples. As results, increased immunoreactive proteins of tumor necrosis factor alpha (TNF-α), PTK2 and p-PTK2 in human IC sections were observed, accompanied with altered urinary parameters. Interestingly, curcumol-treated IC mice showed that intracellular expressions of PTK2, p-PTK2 in bladder samples were reduced, accompanied with lowered blood inflammatory cytokines of interleukin 6 (IL-6), TNF-α. In conclusion, the current bioinformatic data and preliminary findings unravel that the predominant targets of curcumol against IC may be the potential biological markers for screening and treating IC, such as PTK2 molecule.

Citing Articles

Exploring the anti-inflammatory effects of phytochemicals in attenuating interstitial cystitis-a literature review.

Anjum I, Nasir A, Naseer F, Ibrahim A, Rehman B, Bashir F Front Pharmacol. 2025; 16:1483548.

PMID: 39974737 PMC: 11836544. DOI: 10.3389/fphar.2025.1483548.


Network pharmacology and molecular docking technology for exploring the effect and mechanism of high-dose vitamin c on ferroptosis of tumor cells: A review.

Qu J, Lu S, Wang B, Wang S, Yang Z, Tang H Medicine (Baltimore). 2024; 103(20):e38189.

PMID: 38758839 PMC: 11098213. DOI: 10.1097/MD.0000000000038189.


Curcumol: a review of its pharmacology, pharmacokinetics, drug delivery systems, structure-activity relationships, and potential applications.

Zhai S, Wang R, Wang J, Xu X, Niu L, Guo M Inflammopharmacology. 2024; 32(3):1659-1704.

PMID: 38520574 DOI: 10.1007/s10787-024-01447-6.


Bioinformatics approach and experimental validation reveal the hepatoprotective effect of pachyman against acetaminophen-associated liver injury.

Wu K, Qin J, Liu M, Yan X, Guo C Aging (Albany NY). 2023; 15(17):8800-8811.

PMID: 37679038 PMC: 10522380. DOI: 10.18632/aging.205000.


Identification and vitro verification of the potential drug targets of active ingredients of Chonglou in the treatment of lung adenocarcinoma based on EMT-related genes.

Zhao F, Zhao P, Chang J, Sun X, Ma X, Shi B Front Genet. 2023; 14:1112671.

PMID: 36824434 PMC: 9942681. DOI: 10.3389/fgene.2023.1112671.


References
1.
Zhou R, Xu X, Liu M, Wu X, Li R . Immunophenotypes of Ductal Epithelial Cells in Advanced Pancreatic Ductal Adenocarcinoma. Digestion. 2018; 99(3):247-251. DOI: 10.1159/000492861. View

2.
Lane D, Takhar S . Diagnosis and management of urinary tract infection and pyelonephritis. Emerg Med Clin North Am. 2011; 29(3):539-52. DOI: 10.1016/j.emc.2011.04.001. View

3.
Hervent A, De Keulenaer G . Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int J Mol Sci. 2012; 13(10):12268-86. PMC: 3497272. DOI: 10.3390/ijms131012268. View

4.
Verma S, Sharma S . Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders. Curr Mol Pharmacol. 2018; 11(3):191-202. DOI: 10.2174/1874467211666180226161846. View

5.
Elson A . Stepping out of the shadows: Oncogenic and tumor-promoting protein tyrosine phosphatases. Int J Biochem Cell Biol. 2017; 96:135-147. DOI: 10.1016/j.biocel.2017.09.013. View